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This paper illustrates the efficacy of DNA vaccination through electroporation in the prevention of oral transplantable carcinoma in
Syrian hamsters. At 21 and 7 days before tumour challenge, 19 hamsters were vaccinated with plasmids coding for the extracellular
and transmembrane domains of rat HER-2 receptor (EC-TM plasmids), whereas 19 control hamsters were injected intramuscularly
with the empty plasmid. Immediately following plasmid injection, hamsters of both groups received two square-wave 25ms,
375Vcm
 1 electric pulses via two electrodes placed on the skin of the injection area. At day 0, all hamsters were challenged in the
submucosa of the right cheek pouch with HER-2-positive HCPC I cells established in vitro from an 7,12-dimethylbenz[a]anthracene-
induced oral carcinoma. This challenge gave rise to HER-2-positive buccal neoplastic lesions in 14 controls (73.37%), compared with
only seven (36.8%, Po0.0027) vaccinated hamsters. In addition, the vaccinated hamsters displayed both a stronger proliferative and
cytotoxic response than the controls and a significant anti-HER-2 antibody response. Most of the hamsters that rejected the challenge
displayed the highest antibody titres. These findings suggest that DNA vaccination may have a future in the prevention of HER-2-
positive human oral cancer.
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Neoplasms of the oral cavity constitute about 3% of all
malignancies worldwide (Parkin et al, 2001) and their continuous
increase to the point of becoming a public health problem in the
foreseeable has been predicted by the World Health Organization
(http://www.who.int/topics/oral_health/en). Oral squamous cell
carcinoma (OSCC) accounts for about 90% of cases. It may be
preceded by various lesions and is a complex disease because
of its location and patterns of spread. Treatment is essentially
determined by site and stage as well as the patient’s general health
(Vokes et al, 1993). Survival rates, however, have not improved
over the last 20 years and 50–70% of patients die within 5 years
due to local recurrences, metastasis and a second primary cancer
(Day and Blot, 1992). Surgery is still the treatment of choice, but
often results in chronic pain, speech and swallowing impediments,
and irreparable, disfiguring impairments (Mort Telfer and
Shepherd, 1993; de Cassia Braga Ribeiro et al, 2003).
The alarming epidemiological data, the poor prognosis and the
unsatisfactory quality of life of patients with OSCC call for the
urgent elaboration of a new way to treat it. Recent preclinical
and clinical studies of immunopharmacological methods have
shown that they can be effective against melanoma (Nestle et al,
1998; Rosenberg et al, 1998), lymphoma (Hsu et al, 1996), kidney
(Kugler et al, 2000), prostate (Murphy et al, 1999), colorectal
(Morse et al, 1999) and head and neck cancers (Cortesina et al,
1994; Wollenberg et al, 1999; De Stefani et al, 2002). Anticancer
vaccines constitute a specific approach whose efficacy depends on
how well the target tumour antigens are defined and whether there
are conserved antigens shared by tumours of the same histotype
in many individuals (Gilboa, 2004). The literature shows that
HER-2 is one of the most common oncogenes overexpressed in OSCC
(Chen et al, 2003). It encodes for a tyrosine-kinase receptor (p185)
belonging to the family of epidermal growth factor receptors.
Increased expression or mutation of p185 induces a proliferation
signal in a ligand-independent way. p185 is therefore believed to
be involved in the triggering and progression of many epithelial
tumours (Ignatoski et al, 1999). Impressive results have been
achieved by targeting p185, particularly in transgenic mice that
inevitably develop spontaneous tumours. DNA vaccination with
plasmids coding for the transmembrane and extracellular domains
of the rat p185 (EC-TM plasmids) elicits a protective immune
response against spontaneously arising mammary tumours in
BALB/c mice transgenic for the gene encoding the mutated form of
the rat p185 (Rovero et al, 2000; Di Carlo et al, 2001; Dela Cruz
et al, 2003; Quaglino et al, 2004a). This form of vaccination has
many ideal features: induction of both humoral and cellular
immune responses, long-lasting immunity and simple and cheap
production. The first generation of experiments have shown that
delivery of DNA constructs encoding a specific immunogen safely
elicits well-tolerated responses in a variety of animal models
(Lowrie, 2003). Even better results are obtained when the entry of
DNA into target cells is facilitated by electroporation, a technique
in which short high-voltage pulses are used to form pores in the
cell membrane (Gehl, 2003). This paper illustrates the efficacy of
DNA vaccination through EC-TM plasmid electroporation (EC-TM
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sDNA-vax) in the prevention of oral cancer in an orthotopic Syrian
hamster model of transplantable tumour. The OSCC line (HCPC I)
injected into hamster cheek pouches was established from an
epidermoid carcinoma induced through in vivo applications of
7,12-dimethylbenz[a]anthracene (Salley, 1954; Odukoya et al,
1983). Our findings indicate that EC-TM DNA-vax may have a
future in the treatment of HER-2-positive human oral cancer,
especially in the prevention of its development after surgical
removal of an initial OSCC or as the sequel of a precancerous
lesion.
MATERIALS AND METHODS
Cell lines
The HCPC I line established from a chemically induced
epidermoid carcinoma of the Syrian hamster (Odukoya et al,
1983) was kindly provided by Professor DT Wong (UCLA, Los
Angels, CA, USA). N202.1A and N202.1E, which are positive and
negative for rat HER-2 expression, respectively, are clonal
derivatives of the established N202.1 cell line derived from a
mammary carcinoma of FVB-neuN#202 mice, transgenic for the
rat neu proto-oncogene (Nanni et al, 2000). SKBr3 (American Type
Culture Collection, Manassas, VA, USA) is a human breast cancer
cell line that overexpresses the HER-2 gene product. Wild-type
BALB/c 3T3 fibroblasts and BALB/c 3T3 fibroblasts stably
cotransfected with the wild-type rat HER-2/neu and mouse class
I H-2K
d and B7.1 genes (BALB/c 3T3-NKB cells) (Spadaro et al,
2005) were kindly provided by Dr Wei-Zen Wei (Karmanos Cancer
Institute, Detroit, MI, USA). Cells were cultured in DMEM (Sigma-
Aldrich, St Louis, MO, USA) with 75Uml
 1 penicillin G,
100mgml
 1 kanamycin sulphate and 1mgml
 1 amphotericin B
(all from Sigma) at 371C in a humidified 5% CO2 atmosphere. For
HCPC I and SKBr3, the medium was supplemented with 10% fetal
calf serum (FCS) (Cambrex, Walkersville, MD, USA), whereas for
N202.1A, N202.1E, BALB/c 3T3 and BALB/c 3T3-NKB cultures it
was supplemented with 20% FCS. Neomycin (600mgml
 1) and
Zeocin (600mgml
 1) (Invitrogen Corp., Carlsbad, CA, USA) were
added to the BALB/c 3T3-NKB cell medium.
Immunoprecipitation and Western blot analysis
HCPC I, N202.1A and N202.1E cell monolayers were collected and
prepared by homogenisation in protein loading buffer. Total
proteins (20mg) were separated on an 8% SDS–polyacrylamide gel,
and electrotransferred to a Hybond-C nitrocellulose membrane
(Amersham Pharmacia Biotech, Little Chalfont, UK). Western blot
analysis was performed with the mouse monoclonal antibody
(mAb) Ab-3 (Oncogene Research Products, Cambridge, MA, USA).
The membrane was then exposed to the appropriate horseradish
peroxidase-conjugate secondary antibody (1:5000) (Sigma) for 1h
at room temperature and labelled bands were detected with a
chemiluminescence commercial kit (Immun-Start, Bio-RadHercules,
CA, USA). Image acquisition of the immunoreactive bands was
performed with a Kodak Image Station 440CF (Kodak, Rochester,
NY, USA).
Immunoprecipitation of tumour, healthy tissue and HCPC I was
performed by incubating samples with the rabbit polyclonal
antibody Sc-284 (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
and with Protein A-sepharoses (Sigma), equilibrated in lysis buffer
and conjugated with anti-rabbit IgG (Sigma). After immuno-
precipitation, immune complexes were washed, eluted, heated
for 5min at 951C in reducing sample buffer and processed as
described for total samples. Immunoprecipitated proteins were
revealed with a pool of DNA-vax or control hamster sera diluted
1:10, and the secondary antibody peroxidase-conjugated Affini-
Pure Rabbit anti-Syrian hamster IgG (Jackson ImmunoResearch,
West Grove, PA, USA).
Flow cytometry
HCPC I cells were stained with Ab-3, which recognises an
intracellular domain of p185; SKBr3 cells were used as a control
of high Her-2 expression. The anti-mouse FITC-conjugated
secondary antibody (1:5000) (Dako, Glostrup, Denmark) was
used to detect bound primary antibodies. Before staining, the cells
were permeabilised with phosphate-buffered saline (PBS) supple-
mented with 1% FCS and 0.5% Tween 20. Analysis was performed
with a FACscan (Beckton Dickinson, Mountain View, CA, USA)
and the cells were gated by size and granularity. The data were
analysed through CellQuest (Beckton Dickinson).
Hamsters and HCPC I cell challenge
Thirty-eight 4–6-week-old male Syrian hamsters (Charles River
Laboratories Italy, Calco, Italy) were maintained in specific
pathogen-free conditions with a 12h light–dark cycle and rodent
chow and tap water ad libitum. They were challenged (day 0) with
1.8 10
7 HCPC I cells in 0.2ml of PBS injected with a 20-gauge
needle syringe in the submucosa of the everted and stretched out
right cheek pouch. They were then checked weekly to monitor
lesion progression and, 5 weeks from the beginning of the
experiments, anesthetised, bled and killed. The spleen was
collected for the cytotoxicity assay, while all the main organs were
inspected macroscopically. All procedures were carried out in
accordance with the Guidelines for the Welfare of Animals in
Experimental Neoplasia (UKCCCR, 1998).
Injection and electroporation of EC-TM plasmids
pcDNA3 vector coding the extracellular and transmembrane
domains of rat HER-2 receptor was produced and used as
described (Rovero et al, 2000). Briefly, DNA was precipitated,
suspended in sterile saline at 1.25mgml
 1, and stored in aliquots
at  201C for use in immunisation protocols. For DNA electro-
poration, 50mg of EC-TM or empty plasmids in 40ml of 0.9% NaCl
with 6mgml
 1 polyglutamate were injected into the tibial muscle
of both legs of anesthetised hamsters 21 and 7 days before tumour
challenge (day 0). Electric pulses were applied by two electrodes
placed on the shaved skin of the injection area covered with a
conducting gel. Two square-wave 25ms, 375Vcm
 1 pulses were
generated by a T820 electroporator (BTX, San Diego, CA, USA).
Histology and immunohistochemistry
Tissue samples and cells were fixed and embedded in paraffin.
Sections (4mm) were cut and stained with haematoxylin and eosin
or analysed for expression of HER-2 using the Sc-284 Ab, or of
pancytokeratins with the C-1801 mouse mAb (Sigma). The binding
of Sc-284 on fixed samples was evaluated with a Dako En Visiont
Plus System (Dako Corporation, Carpinteria, CA, USA). Per-
oxidase activity was displayed by 3–30-diaminobenzidinetetra-
hydrochloride (Dako Corporation) and a haematoxylin solution
was used for nuclear staining. Paraffin sections from mammary
carcinomas with known HER-2 expression were used as positive
controls. Staining was graded from 0 (negative) to 3 (strong
complete membrane staining) according to the manufacturer’s
instructions (Dako Hercept Test, 2000). On fresh cells growing on
a Lab-Tek chamber slide (Nalge Nunc Int, Naperville, IL, USA),
after nuclear staining with propidium iodide, Sc-284 and C-1801
binding was demonstrated with the appropriate FITC-conjugated
Ab. Images were captured with an Axiovert Zeiss microscope
(Zeiss, Axiovert 100 M).
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sCellular reactivity
In the proliferative assay, 4 10
5 spleen cells (Spc) from control
and EC-TM DNA-vax hamsters were cultured with 2 10
4 HCPC I
cells in 200ml of medium supplemented with 10Uml
 1 of
recombinant IL-2 (Eurocetus, Milan, Italy) in quadruplicate in
microtitre wells at 371C in a humidified 5% CO2 atmosphere. After
24h, cells were pulsed for 48h with BrdU labelling solution. BrdU
uptake was detected with the Cell Proliferation ELISA BrdU Kit
(Roche Diagnostic GmbH, Mannheim, Germany) and expressed as
optical density (OD). To assess cytotoxicity, 1 10
7 Spc were
stimulated for 6 days with 5 10
5 mitomycin-C (Sigma)-treated
HCPC I cells in the presence of 10Uml
 1 IL-2 and assayed in a
48h [
3H]TdR release assay at effector-to-target ratios from 50:1 to
6:1 in round-bottom, 96-well microtitre plates in triplicate, as
previously described in detail (Cappello et al, 2003). The results
were expressed both as percentage of cytotoxicity and as lytic units
(LU)20 per 10
7 effector cells, with LU20 defined as the number of
effector cells needed to kill 20% of the target cells (Cavallo et al,
1992).
Antibody response
Sera obtained at progressive time points from control and EC-TM
DNA-vax hamsters were diluted 1:100 in PBS-azide-bovine serum
albumin (Sigma), and the presence of anti-p185 Ab was
determined by flow cytometry using BALB/c 3T3-NKB cells.
FITC-conjugated goat anti-hamster Ab specific for hamster IgG
(heavy and light chains) (ImmunoKontact, Abingdon, Oxon, UK)
was used to detect bound primary Ab. Normal hamster serum was
the negative control. mAb Ab-4 (Oncogene) was used as a positive
control. Serial Ab-4 dilutions were used to generate a standard
curve to determine the concentration (mgml
 1) of anti-p185 Ab in
serum (Spadaro et al, 2005).
Statistics
Differences in tumour numbers were evaluated using Fisher’s exact
test. Data on cytotoxicity, lymphocyte proliferation and antibody
level were evaluated with a two-tailed Student’s t-test.
RESULTS
HER-2 expression by HCPC I cells
As shown by Western blot analysis with mouse N202.1A and
N202.1E cells as HER-2-positive and -negative controls, HCPC I
cells express p185 receptor (Figure 1A).
Immunostaining of adhering cells (Figure 1B) showed a
predominant cell membrane p185 expression; immunohisto-
chemistry of paraffin-embedded HCPC I (Figure 1C, D) showed
a medium-high p185 expression (2þ) in almost all cells (as
compared with breast carcinoma specimens, not shown, according
to the manufacturer’s instructions) (Dako Hercept Test, 2000).
After staining the cells with Ab-3 recognising p185, flow cytometry
showed that HCPC I cells were HER-2 positive (Figure 1E). SKBr3,
which are known to highly overexpress HER-2, were used as a
positive control (Figure 1F).
Growth of HCPC I tumour cells in Syrian hamsters
At 5 weeks after HCPC I cell challenge, 14 out of 19 hamsters
(73.37%) injected with the empty plasmid 21 and 7 days before
challenge displayed buccal lesions (mean 3–11mm). Six hamsters
presented small nodules, three of which were associated with
mucosal ulceration, while eight showed irregularly shaped white
plaques. Irrespective of the gross appearance, all lesions had
the microscopical features of invasive squamous carcinoma. The
lesions were characterised by solid nests and cords composed of
large roundish or, more commonly, elongated neoplastic cells, with
occasional atypias, an hyperchromatic nucleus and numerous
mitoses, extensively infiltrating the wall of the pouch mucosa and
underlying striated muscle fibres. In some cases, the overlying
mucosa was invaded and ulcerated. Keratin pearls and multi-
nucleated cells were occasionally observed. Foci of necrosis were
present in most cases (Figure 2A and B). The epithelial origin
of the infiltrating cells was confirmed by immunohistochemical
expression of cytokeratin (Figure 2C, D and E). The tumour cells
were also focally positive for HER-2, with preferential peripheral or
membrane staining (Figure 2F). In the five tumour-free hamsters,
the whole tissue challenge areas displayed only an inflammatory
and fibrotic reaction. A dense fibrous tissue nodule containing
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Figure 1 p185 expression by HCPC I. (A) Western blot analysis revealed by Ab-3: N202.1E is the negative control, N202.1A the positive control; the
arrow indicates a molecular weight of 185kDa; (B) Sc-284 p185 localisation in adherent HCPC I shown by green fluorescent immunostaining. Nuclei are
stained red. (Original magnification: 600). (C, D) Immunocytochemical expression of p185 by HCPC I revealed by Sc-284. A predominant membrane
staining is shown (original magnification: C  200; D  1000). (E, F) FACs analysis performed with mAb Ab-3. In (E) HCPC I staining is shown, and in (E)
SKBr3 are used as a positive control.
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soccasional inflammatory cells, but no tumour cells (as confirmed
by negative cytokeratin staining) was seen in two hamsters (data
not shown).
Anti-HER-2 DNA vaccine protects against HCPC I cell
challenge
Only seven out of 19 (36.8%, Po0.0027) hamsters vaccinated with
EC-TM plasmids 21 and 7 days before challenge displayed a
neoplastic lesion. Five displayed a nodular mass, the other two a
white plaque only. The histological features of these lesions were
similar to those of the controls. No signs of acute toxicity or weight
differences were associated with EC-TM DNA-vax.
Cell reactivity
To see whether enhanced cell reactivity was associated with the
protection afforded by EC-TM DNA-vax, the proliferative and
cytotoxic response of Spc from EC-TM-vaccinated and control
hamsters to HCPC I cells was assessed at the end of the
experiment. Following in vitro restimulation, Spc from EC-TM-
vaccinated hamsters displayed a stronger proliferative (Figure 3A)
and cytotoxic response (Figure 3B) than those from control
hamsters.
Anti-HER-2 antibodies
A significant anti-HER-2 antibody response was detected in sera
collected the day before HCPC I challenge from the immunised
hamsters. Most of the hamsters that rejected the challenge
displayed the highest antibody titres (Figure 4A). These titres
were much the same 5 weeks later.
The specificity of those antibodies was confirmed by Western
blot. After immunoprecipitation, sera from DNA-vax hamsters
recognised the p185 expressed by HCPC I and by tumour tissue
but not from healthy controlateral pouch mucosa (Figure 4B).
No staining was obtained by sera of control hamsters (data not
shown).
DISCUSSION
This is probably the first demonstration that a protective immune
response against HER-2 can be elicited in hamsters by EC-TM
DNA-vax as in mice transgenic for the rat HER-2 that develop
mammary carcinomas (Rovero et al, 2000; Quaglino et al, 2004a).
Electroporation of plasmids coding for the EC and TM portion of
rat HER-2 elicits both T-cell reactivity and antibody response. The
direct correlation between the anti-HER-2 Ab titre and rejection of
HCPC I suggests that antibodies make a substantial contribution to
this protection as in HER-2 transgenic mice (Rovero et al, 2000;
Nanni et al, 2004; Park et al, 2005).
Plasmids coding rat HER-2 were employed because xenogeneic
immunisation is an effective way to break tolerance and induce
T cells and antibodies crossreacting with the self, tolerated
protein (Bowne et al, 1999; Overwijk et al, 1999). Hamster and
rat HER-2 proteins share 94.2% sequence similarity (Swiss Prot;
www.expasy.org) and long homologous sequences are intercalated
with heterologous amino-acid sequences. T-helper cell reactivity
against non tolerated rat peptides assists activation of the B
cells that will produce antibodies against both rat and hamster
HER-2 (Trojan et al, 2001). Moreover, in the nine fragments
recognised as the most immunogeneic of the EC and TM domains
according to Ogiso et al (2002), six out of 10 substitutions are
conservative. In addition, xenogeneic sequences may give
rise to ‘heteroclitic’ peptides that may have a higher affinity for
hamster MHC glycoproteins than homologous peptides (Dyall
et al, 1998).
Vaccination with DNA coding for rat HER-2, in fact, elicits a
significant cell (P¼0.009) and antibody (P¼0.0024) reaction
Figure 2 Histology and immunohistochemistry of neoplastic lesions induced in hamster cheek pouches by HCPC I. (A) Undifferentiated SCC ( 25). At
higher magnification (B,  400), cellular pleomorphism, numerous mitoses and large hyperchromatic nuclei are present in elongated neoplastic cells.
Haematoxylin and eosin staining. Indirect immunofluorescent staining for pancytokeratin confirms the epithelial origin of the tumour infiltrating cells (C,
 25, E,  200). The positive control is the normal epithelium (D,  200). p185 expression is maintained in inoculated HCPC I cells with a predominant
peripheral or membrane cell distribution (F, immunoperoxidase,  400).
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sagainst hamster HER-2. The absence of obvious autoimmune
lesions may be due to poor expression of HER-2 by adult hamster
tissues.
The appearance of a significant anti-HER-2 antibody response
following electroporation points to T-helper and B-cell activation.
Previous work with transgenic mice has illustrated the funda-
mental role of antibodies in checking the progression of HER-2
carcinoma (Rovero et al, 2000; Nanni et al, 2004; Quaglino et al,
2004a; Park et al, 2005). An arbitrary threshold of 11.5mgml
 1 can
be used to divide the vaccinated hamsters into those with high and
those with low anti-HER-2 antibody titres. Tumour takes were
higher in the low-titre hamsters (Figure 4A). The antitumour
effects of antibodies directed against membrane tyrosine kinase
receptors such as p185 include the blockade of mitogenic signal
transduction through inhibition of receptor dimerisation and
induction of internalisation and recycling, along with immune-
mediated functions, namely complement-mediated cytotoxicity
and antibody-dependent cellular cytotoxicity (Rovero et al, 2000;
Nanni et al, 2004; Quaglino et al, 2004b). Although transplantable
tumours may not reflect a few features of the human cancer, we
studied HCPC I cells because the biological and histological
characteristics of the tumours they form in hamsters are actually
very similar to human SCC. In addition, they are from one of the
best-characterised animal models for oral cancer, overexpresses
p185 receptors and are transplantable to immunocompetent
random-bred hamsters. This is probably the first demonstration
of the efficacy of specific immunisation in the control of OSCC. Its
significance is enhanced by the fact that a high percentage of OSCC
overexpresses p185 receptors (Xia et al, 1999; Chen et al, 2003) and
its extension, via a similar protocol, to another kind of cancer,
of the evidence of the ability of DNA electroporation to evoke
an efficient immune response to prevent mammary carcinoma in
HER-2 transgenic mice (Quaglino et al, 2004a). Hamsters are
naturally tolerant to the self-endogenous p185 protein and DNA
electroporation overcame such tolerance. The hamster cheek
pouch is an ideal site for the implantation of tissues and cells,
both from other species and humans (Lutz and Patt, 1952; Handler
et al, 1956; Resnick et al, 1960), since it is not an immunologically
privileged site and immunosuppressive and immunostimulating
agents can modulate the intensity of the local immune response
(Shklar et al, 1979). Transplantability of HCPC I cells to random-
bred hamsters rests on the monomorphic aspect of their major
histocompatibility complex (Billingham and Hildemann, 1958;
Palm et al, 1967). This peculiarity serves to illustrate the efficacy of
DNA vaccination against HER-2 in a genetically heterogeneous
(not inbred) population displaying some features similar to those
in human. This heterogeneity may account for the much higher
dispersion of the anti-HER-2 Ab titres after DNA electroporation
by comparison with inbred mice (Rovero et al, 2000; Quaglino
et al, 2004a,b).
As no major toxic effects were associated with DNA electro-
poration, or with the stimulation of a significant anti-HER-2
immune response, the use of DNA electroporation could be
considered in OSCC prevention, especially the predominantly local
and regional recurrences noted in OSCC patient. Furthermore, it is
a relatively low-cost technology that could also be afforded by
developing countries, such as India, Bangladesh and Sri Lanka
with their high incidence of OSCC and prevalence of HER-2-
positive OSCC due to the consumption of betel quid (Chen et al,
2003).
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Figure 3 Cellular reactivity. (A) Proliferative response. Spc were
restimulated for 48h with HCPC I cells in the presence of BrdU. Results
are from one of three independent experiments in which each sample was
prepared in triplicate (*Po0.05). (B) Cytotoxicity. Spc cytotoxicity
evaluated in a 48h [
3H]thymidine release assay against HCPC I (filled
squares, hamsters vaccinated with EC-TM plasmids; empty squares
hamsters vaccinated with empty plasmid) (P¼0.009). Data from an
experiment representative of three similar experiments are shown.
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Figure 4 Specific antibodies against p185. (A) Anti p185-antibody titre
in vaccinated and control animals. Mean antibody titres are indicated by
full line (**P¼0.0024). Antibody titre of EC-TM DNA-vax hamsters is
correlated to vaccination outcome: black and empty triangles represent
tumour-rejecting and tumor-bearing animals, respectively. Only two out of
seven tumour-bearing hamsters displayed an antibody titre above
11.5mgml
 1 (dotted line). (B) Extracts of healthy mucosa (lane 1), tumour
tissue (lane 2) and HCPC I (lane 3) immunoprecipitated by Sc-284 and
revealed with pooled sera from DNA-vax hamsters. The arrow indicates a
molecular weight of 185kDa.
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